The move would allow the European Medicines Agency to advise
countries that wanted to use the U.S. pharma giant's promising antiviral
treatment ahead of formal approval across the EU.
"EMA is reviewing currently available data on the use
of Paxlovid, an oral treatment for COVID-19 developed by Pfizer," the
Amsterdam-based European Medicines Agency (EMA) said.
"EMA is starting this review to support national authorities
who may decide on its early use for COVID-19, for example in emergency use
settings, prior to marketing authorisation," it said.
A full "rolling review" for formal approval is
expected to start next week but the EMA said it wanted to be able to help
national authorities "in the shortest possible timeframe".
(With input from agencies)
0 comments:
Post a Comment